scholarly journals Identifying the Propofol Binding Site(S) in Heterologously Expressed Human Alpha1 Beta3 Gaba-A Receptors using a Photoreactive Propofol Analog

2013 ◽  
Vol 104 (2) ◽  
pp. 637a ◽  
Author(s):  
Selwyn S. Jayakar ◽  
Xiaojuan Zhou ◽  
Zuzana Dostalova ◽  
William P. Dailey ◽  
Keith W. Miller ◽  
...  
Keyword(s):  
2020 ◽  
Vol 118 (3) ◽  
pp. 580a
Author(s):  
Brandon Pressly ◽  
Heike Wulff ◽  
Ruth Lee
Keyword(s):  

2019 ◽  
Vol 176 (24) ◽  
pp. 4760-4772 ◽  
Author(s):  
Daniel E. Kent ◽  
Pavel Y. Savechenkov ◽  
Karol S. Bruzik ◽  
Keith W. Miller
Keyword(s):  

2009 ◽  
Vol 96 (3) ◽  
pp. 487a
Author(s):  
Joe Henry Steinbach ◽  
John R. Bracamontes
Keyword(s):  
Gaba A ◽  

2020 ◽  
Vol 6 (5) ◽  
pp. 38-45
Author(s):  
T. Gendugov ◽  
A. Glushko ◽  
A. Chiriapkin ◽  
V. Chiriapkin

The article considers the study in silico of the affinity of 3-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-4(3H)-quinazolinone (VMA-10-21 compound) to the benzodiazepine binding site of the GABA А receptor by molecular docking method. The computational experiment was carried out using a set of Autodock programs. As a result, the method for predicting the affinity of the simulated compounds to the benzodiazepine binding site of the GABA A receptor was developed. The highest correlation coefficient between the pKi value and the average docking energy in the benzodiazepine binding site (0.54) was obtained using a set of amino acids Tyr 58 and Tyr 159. The predicted Ki value of the VMA-10-21 compound is 2.864 nM, which suggests a high affinity of the studied compound to this receptor.


2019 ◽  
Vol 116 (3) ◽  
pp. 392a
Author(s):  
Selwyn S. Jayakar ◽  
Xiaojuan Zhou ◽  
Bo Wu ◽  
Keith W. Miller ◽  
Karol S. Bruzik ◽  
...  
Keyword(s):  
Gaba A ◽  

1995 ◽  
Vol 38 (1) ◽  
pp. 16-20 ◽  
Author(s):  
Bruce E. Maryanoff ◽  
Winston Ho ◽  
David F. McComsey ◽  
Allen B. Reitz ◽  
Philip P. Grous ◽  
...  

2014 ◽  
Vol 28 (S1) ◽  
Author(s):  
Roshan Puthenkalam ◽  
Zdravko Varagic ◽  
Anna Dereky ◽  
Chonticha Suwattanasophon ◽  
Isabella Sarto‐Jackson ◽  
...  

2017 ◽  
Vol 119 ◽  
pp. 100-110 ◽  
Author(s):  
Zhenglan Chen ◽  
Ran Liu ◽  
Shao-Hua Yang ◽  
Glenn H. Dillon ◽  
Renqi Huang

2007 ◽  
Vol 35 (3) ◽  
pp. e20-e20 ◽  
Author(s):  
Timothy E. Reddy ◽  
Boris E. Shakhnovich ◽  
Daniel S. Roberts ◽  
Shelley J. Russek ◽  
Charles DeLisi

Author(s):  
Udayan Majumder ◽  
Rajesh Das ◽  
Rajkumar Lenin Singh

Zolpidem is a non-benzodiazepine sedative hypnotic that binds to the benzodiazepine binding site on the gammaaminobutyric acid type A (GABA-A) receptors. It is the most commonly prescribed sleep medication which has been shown to be effective for treating insomnia on a short-term basis with fewer side effects than traditional benzodiazepines, which are feared for their abuse and dependence potential. Many studies have reported efficacy and safety of zolpidem in treatment of insomnia keeping in mind about its low abuse, and dependence capability. We present a case of zolpidem dependence in a 36-year-old male to emphasize that zolpidem also should be judiciously prescribed under supervision so that it does not develop tolerance, abuse and dependence.


Sign in / Sign up

Export Citation Format

Share Document